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Using a high throughput screening methodology we surveyed a collection of largely uncharacterized
validated or suspected kinase inhibitors for anti-human cytomegalovirus (HCMV) activity. From this
screen we identiﬁed three structurally related 5-aminopyrazine compounds (XMD7-1, -2 and -27) that
inhibited HCMV replication in virus yield reduction assays at low micromolar concentrations. Kinase
selectivity assays indicated that each compound was a kinase inhibitor capable of inhibiting a range of
cellular protein kinases. Western blotting and RNA sequencing demonstrated that treatment of infected
cells with XMD7 compounds resulted in a defect in the production of the major HCMV transcriptional
transactivator IE2 proteins (IE2-86, IE2-60 and IE2-40) and an overall reduction in transcription from the
viral genome. However, production of certain viral proteins was not compromised by treatment with
XMD7 compounds.
Thus, these novel anti-HCMV compounds likely inhibited transcription from the viral genome and
suppressed production of a subset of viral proteins by inhibiting IE2 protein production.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
A number of drugs for the treatment of human cytomegalovirus
(HCMV) disease are available for clinical use, including the frontline
drug ganciclovir (GCV) (Coen and Schaffer, 2003; Mocarski et al.,
2015). However, these drugs have many shortcomings, including
the emergence of drug resistant viruses (Coen and Schaffer, 2003).
To develop new anti-HCMV drugs our knowledge of compounds
with anti-HCMV activity must be expanded. Identiﬁcation of
compounds that inhibit the function of HCMV proteins essential for
HCMV replication would be valuable. However, identiﬁcation of
compounds that inhibit the function of cellular proteins required
for HCMV replication should also be explored, as targeting cellular
factors may preclude the emergence of drug resistant viruses.
Several cellular kinase proteins involved in HCMV replication are
required for production of immediate-early (IE) viral proteins IE1
and IE2, an innate and intrinsic immunity antagonist and a tran-
scriptional transactivator, respectively (Mocarski et al., 2015). Pro-
duction of IE proteins leads to a viral transcriptional cascade
(immediate-early to early to late gene transcription) necessary for
the production of infectious HCMV (Mocarski et al., 2015). There-
fore, inhibition of cellular protein kinases could lead to reduced IE
protein production and HCMV replication. However, our under-
standing of how cellular protein kinases are involved in HCMV
replication is incomplete and it is likely that several kinase proteins
required for IE protein production have to yet be identiﬁed.
We have previously developed a high throughput siRNA
screening methodology to identify siRNAs that positively or nega-
tively inﬂuence HCMV protein production (Polachek et al., 2016).
Here, we adapted this methodology to identify compounds that
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inhibit HCMV protein production. We then sought to expand our
understanding of compounds that can be developed to anti-HCMV
drugs by applying our screen to the Gray Kinase inhibitor library; a
collection of compounds, many of which have not been previously
characterized, comprising validated and suspected ATP-site kinase
inhibitors that target active and inactive kinase conformations of
cellular kinase proteins.
2. Materials and methods
2.1. Compounds
The Gray Kinase Inhibitor library was supplied to the Institute of
Chemistry and Chemical Biology-Longwood at Harvard Medical
School by Nathanael S Gray. Any available information on com-
pounds within the Gray Kinase Inhibitor library can be found at the
Harvard Medical School (HMS) LINCS online resource (http://lincs.
hms.harvard.edu/), which is part of the National Institutes of Health
Library of Integrated Network-based Cellular Signatures (LINCS)
Program or is available by request from Nathanael S Gray. All drugs
were resuspended in dimethyl sulfoxide (DMSO).
2.2. Cells and viruses
Human foreskin ﬁbroblast (HFF) cells (clone Hs29) were ob-
tained from American Type Culture Collection no. CRL-1684 (ATCC,
Manassas, VA) and maintained in Dulbeccos modiﬁed Eagles me-
dium (DMEM) (Gibco) containing 5% fetal bovine serum (FBS)
(Gibco), plus penicillin and streptomycin. High passage HCMV
strain AD169 was a gift from Don Coen (Harvard Medical School).
Low passage strain Merlin RCMV1111 (derived from BACmid
pAL1111, which does not express RL13 and UL128) (Stanton et al.,
2010) was a gift from Richard Stanton (Cardiff University).
2.3. High throughput screening of compounds
See Supplementary Material.
2.4. Synthesis of XMD7 compounds
See Supplementary Material.
2.5. Viral yield reduction assays
5  104 HFF cells per well were plated in 24-well plates. Cells
were incubated overnight and then infected with HCMV at a mul-
tiplicity of infection (MOI) of 1. Virus was adsorbed to cells for 1 h at
37 C and then cells were incubated with 0.5 ml of media con-
taining DMSO or compounds at a range of concentrations in
duplicate. Plates were incubated for 96 h at 37 C. Viral titre (plaque
forming units (p.f.u.) per ml) was determined by titration of viral
supernatants on HFF monolayers. The mean value of duplicate
plaque counts was calculated. The ﬁnal concentration of DMSO in
all samples was maintained at <1% (v/v).
2.6. MTT assays
1  104 HFF cells per well were plated in 96-well plates. Cells
were incubated overnight and then treated for the time indicated in
the text with compounds at range of concentrations in duplicate.
Relative cell number was then determined with an MTT assay ac-
cording to the manufacturer's instructions (GE Healthcare). The
mean value of duplicate readings was calculated. The ﬁnal con-
centration of DMSO in all samples wasmaintained at <1% (v/v). As a
positive control, in all experiments a 2-fold dilution series of HFF
cells starting at 1  104 cells per well was included. In each
experiment we found a linear relationship between the number of
cells per well and output from the MTT assay (data not shown).
2.7. Kinase selectivity analysis
Each compound was submitted to DiscoverX for Ambit KIMO-
MEscan analysis on a panel of 353 kinase proteins in the presence of
10 mM of each compound. Information concerning each kinase
protein assayed can be found at www.discoverx.com.
2.8. Western blotting
At time points indicated in the text cells were washed once with
PBS and resuspended in 100 ml Laemmli buffer containing 5% b-
mercaptoethanol. Proteins were separated on 8% or 10% poly-
acrylamide gels. Membranes were probed with antibodies recog-
nizing IE1/2, pp28, pp65, UL44, UL84, (Virusys, 1:1000 dilution), IE2
proteins (clone 5A8.2, Millipore, 1:1000 dilution) and b-actin
(SIGMA, 1:5000 dilution). All primary antibodies were detected
using anti-mouse- or anti-rabbit-horseradish peroxidase (HRP)
conjugated antibodies (Millipore and Cell Signaling Technology,
respectively). Chemiluminescence solution (GE Healthcare) was
used in each case to detect secondary antibodies using ﬁlm. Rela-
tive band intensity (band intensity relative to b-actin signal in the
same lane) was analyzed using ImageJ software, obtained from the
National Institutes of Health (USA).
2.9. Preparation of RNA for sequencing
5  106 HFF cells were infected with HCMV strain AD169 at an
MOI of 1 in the presence of DMSO or 1 mM XMD7-1. At 24, 48 and
72 h.p.i., cells were trypsinized, pelleted and stored at 80 C. Total
infected cell RNAwas isolated by using an RNeasyMidi Kit (Qiagen).
To generate sequencing libraries RNA was prepared using either a
Globin-Zero Gold rRNA Removal Kit to remove rRNA, or a module of
an Illumina TruSeq Stranded mRNA Library Prep Kit to select
poly(A) RNA, followed by the remaining modules of an Illumina
TruSeq Stranded mRNA Library Prep Kit.
2.10. RNA sequencing and analysis
The sequencing libraries were analyzed on an Illumina MiSeq,
collecting single-end data sets of 75 nucleotides. The sequence of
HCMV strain AD169 in GenBank accession BK000394 was used to
align read data and specify sequences representing exon-exon
junctions. Whole genome transcriptome proﬁles were visualized
by using Artemis (Carver et al., 2012), and reads representing exon-
exon junctions were enumerated by using the Unix grep program.
3. Results
3.1. High throughput screening of a compound library
We screened the Gray Kinase Inhibitor library of 187 compounds
(Table S1) for anti-HCMV activity using a methodology based on
our previous siRNA screening experiments (Polachek et al., 2016).
Brieﬂy, HFF cells were treated with each compound from the
collection and infected with HCMV strain AD169. Cells were then
stained with antibodies to detect the HCMV antigen pp28. As pp28
is expressed late in infection, detection of pp28 allowed our screen
to identify compounds affecting all stages of HCMV replication from
entry of virus into the cell to late gene expression. The total number
of cells and the number of infected cells were enumerated using
automated microscopy. In wells where the mean number of cells
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was 2-fold below the mean number of cells of the plate, the com-
pound in that well was judged to be cytotoxic (41 compounds,
Table S2). Data from compounds not excluded for cytotoxicity were
converted to a z-score (the number of standard deviations from the
mean of the data (Birmingham et al., 2009; Zhang et al., 1999)) to
show an increase or decrease (positive or negative z-score,
respectively) in the number of pp28 positive cells (146 compounds,
Fig. 1 and Table S3).
The “hit” in our screen with the greatest negative z-score was a
previously uncharacterized 5-aminopyrazine compound, XMD7-1
(Fig. 1). We also found that two other previously uncharacterized
5-aminopyrazine compounds structurally related to XMD7-1,
XMD7-2 and XMD7-27, were assigned negative z-scores (Fig. 1).
3.2. Inhibition of HCMV replication by XMD7 compounds
To conﬁrm the anti-HCMV activity of XMD7 compounds, we
used viral yield reduction assays to assess replication of high pas-
sage HCMV strain AD169 and low passage HCMV strain (Merlin
(RCMV1111)), whose genomic content is similar to that of a clinical
virus (Wilkinson et al., 2015), in the presence of XMD7 compounds.
The 50% effective dose (ED50) of each compound against AD169
and Merlin was 0.3e0.4 mM and 2.1e2.5 mM, respectively. There-
fore, XMD7 compounds were inhibitors of HCMV replication and
had anti-HCMV activity against different strains of HCMV.
To ensure that the anti-HCMV activity of XMD7 compounds was
not due to cellular cytotoxicity or inhibition of cell division, we used
an MTT assay to assess relative cell number in uninfected cells in
the presence of these compounds compared to treatment of cells
with DMSO. We found that the 50% cellular cytotoxicity (CC50) of
each XMD7 compound was greater than 10 mM (Table 1). Therefore,
the CC50 of each compound was at least 10-fold greater than the
ED50 of compounds. Thus, the observed anti-HCMV activity of
XMD7 compounds was unlikely to have been due to their cyto-
toxicity or inhibition of cell division. Consistent with this conclu-
sion, we observed no obvious cell death or changes to cell
morphology at any time after treatment of uninfected cells with
XMD7 compounds (data not shown).
3.3. Kinase selectivity analysis of XMD7 compounds
We then sought to understandwhether XMD7 compoundswere
kinase inhibitors and to determine which kinase proteins they
could inhibit. We subjected each compound to Ambit KINOMEScan
analysis, wherein the ability of each compound to inhibit a panel of
353 cellular kinase proteins was assayed.We found that each XMD7
compound inhibited a similar range of kinase proteins, albeit with
different potencies (Fig. 2AeC and Tables S4eS6). Therefore, inhi-
bition of HCMV replication in the presence of XMD7 compounds
was likely related to their ability to inhibit the function of the
cellular kinase proteins shown in Fig. 2AeC.
Furthermore, we used western blotting to investigate auto-
phosphorylation of the HCMV encoded kinase UL97 in the presence
of XMD7-1. UL97 autophosphorylationwas not affected by XMD7-1
(data not shown). Therefore, the anti-HCMV activity of XMD7
compounds was unlikely to have been due to inhibition of UL97.
3.4. Examination of events early in HCMV replication
We then sought to understand how XMD7 compounds inhibit
HCMV replication. To investigate if XMD7-1 could affect virus entry
into the cell or translocation of the HCMV genome to the nucleus,
Fig. 1. Compounds assigned z-scores. Plot of z-scores where each data point represents a single compound. A list of each compound with its assigned z-scores is shown in
Supplementary Table S3. The structures and z-scores (stated in parentheses) of XMD7-1, -2 and -27 are identiﬁed.
Table 1
Anti-viral activity and cytotoxicity of XMD7 compounds.
Assay Viral Strain Compound ED50a CC50a
Viral Yield Reductionb AD169 XMD7-1 0.3 e
AD169 XMD7-2 0.3 e
AD169 XMD7-27 0.4 e
Viral Yield Reductionb Merlin (RCMV1111) XMD7-1 2.5 e
Merlin (RCMV1111) XMD7-2 2.1
Merlin (RCMV1111) XMD7-27 2.4
MTT Cytotoxicityc e XMD7-1 e >10
e XMD7-2 e >10
e XMD7-27 e >10
a mM.
b Viral titre was assessed at 96 h post infection in the presence of each compound.
c MTT assays were carried out after 96 h exposure of cells to each compound.
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we treated AD169 infected HFF cells with 1 mM XMD7-1 at 24 h.p.i.
We found an approximately 2-fold decrease in HCMV replication at
120 h.p.i., compared to infected cells treated with DMSO at 24 h.p.i.
(data not shown). Therefore, XMD7-1 could inhibit HCMV replica-
tion after HCMV entry and the inhibitory effects of XMD7-1 were
likely related to inhibition of events after entry of the virus into the
cell.
Next, we used western blotting to assay HCMV IE protein pro-
duction in the presence of XMD7-1. IE1-72 and IE2-86 are produced
by alternative splicing of mRNA transcripts produced from the
UL122-123 locus (Fig. 3A). Other IE2 proteins, IE2-60 and IE2-40,
are produced from internal start codons within exon 5 of the
UL122-123 locus (Fig. 3A). When comparing protein production in
the presence of XMD7-1 (Fig. 3B, lanes 5e7) to treatment with
DMSO (Fig. 3B, lanes 2e4), we found that XMD7-1 had no effect on
the production of IE1-72, but resulted in a 3-fold and 6-fold
decrease in IE2-86 at 72 h.p.i. (Fig. 3B, top and second to top
panels, respectively) and a 9- and 2-fold reduction in production of
IE2-60 and IE2-40 72 h.p.i., respectively. Similar results were
observed when infected cells were treated with XMD7-2 or XMD7-
27 (data not shown). Therefore, the anti-HCMV activity of XMD7
compounds was associated with suppression of IE2 protein
production.
3.5. Analysis of HCMV RNA production and splicing
We then considered why IE2, but not IE1, protein production
was inhibited in the presence of XMD7-1. We found that each
XMD7 compound was a potent inhibitor of CLK proteins -1, -2, -3
and -4 (indicated with asterisks in Fig. 2AeC) and treatment of
HCMV infected cells with XMD7-1 resulted in an increase in CLK-1
protein (data not shown), which is consistent with XMD7-1 acting
as a CLK kinase inhibitor (Ninomiya et al., 2011). RNA splicing is
modulated by the SRSF family of proteins and SRSF protein function
can be inﬂuenced via phosphorylation by CLK proteins. Therefore,
we hypothesized that treatment of HCMV infected cells with
Fig. 2. Kinase selectivity of XMD7 compounds. (A)e(C) Each compound (XMD7-1, -2 and -27, respectively) was subjected to Ambit KINOMEScan analysis. Each ﬁgure shows the
123 kinase proteins most potently inhibited by each compound. Full lists of kinase inhibition data for XMD7-1, -2 and -27 are shown in Tables S4eS6, respectively. Asterisks and
crosses denote the ability of each compound to inhibit CLK proteins or CDK7, respectively.
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XMD7-1 resulted in suppression of SRSF phosphorylation and de-
regulation of the alternative mRNA splicing producing transcripts
encoding either IE1 or IE2.
We addressed SRSF phosphorylation using western blotting. A
decrease in phosphorylation of SRSF protein SRSF4, but not any
other SRSF protein, was observed (data not shown). However,
treatment of HCMV infected cells with siRNA targeting mRNA
encoding SRSF4 had no obvious effect on production of infectious
Fig. 3. Western blotting and RNA sequencing from HCMV infected cells treated with XMD7-1. (A) Organization of HCMV sequences encoding IE1/2 proteins and IE1/2 proteins
produced during HCMV replication. The 5 exons of the HCMV UL122-123 locus that encode IE1 and IE2 proteins are shown. Black arrows in exons 2 and 5 represent start codons.
Above the exons are the exon-exon junctions. Below the exons the alternative spicing of RNAs that encode IE1 and IE2 proteins is shown, as are IE2 proteins IE2-60 and IE2-40
produced from internal start sites in exon 5. (B and D) HFF cells were infected with AD169 at an MOI of 1, then treated with either 1 mM XMD7-1 or the equivalent volume of
DMSO at the time of infection. Cell lysates were prepared for western blotting at the time points (hours post infection (h.p.i.)) indicated above the ﬁgure. Uninfected cells harvested
at the time of infection are shown as 0 h.p.i. Proteins recognized by the antibodies used are indicated to the right of each ﬁgure. The positions of molecular mass markers (kDa) are
indicated to the left of each ﬁgure. (C) Number of HCMV RNA sequence reads from total RNA (excluding rRNA) from HFF cells infected with AD169 at an MOI of 1, then treated with
either 1 mM XMD7-1 or the equivalent volume of DMSO at the time of infection.
R. Beelontally et al. / Antiviral Research 138 (2017) 61e67 65
HCMV (data not shown). Therefore, the anti-HCMV effect of XMD7-
1 was unlikely to involve inhibition of SRSF4 phosphorylation.
To assess viral RNA production and splicing, total RNA was iso-
lated from HCMV infected cells treated with XMD7-1 and, after
removal of rRNA, RNAwas sequenced and the sequence reads were
aligned to the genomic sequence of AD169. We found approxi-
mately 2-fold fewer total number of HCMV sequences reads in cells
treatedwith XMD7-1 compared to cells treatedwith DMSO (Fig. 3C)
across the entire HCMV genome (data not shown). We then
analyzed the RNA sequence reads for the presence of a selection of
exon-exon junctions within HCMV RNA transcripts (Gatherer et al.,
2011). Treatment with XMD7-1 resulted in a general decrease in the
number of reads representing junctions, including those encoding
IE1 or IE2 (Fig. 3A) at 24, 48 and 72 h.p.i. (Table S7), which likely
parallels the reduction in the total number of HCMV sequence reads
(Fig. 3C). To ensure that this analysis was not biased by the method
of RNA sample preparation, we performed a similar analysis of the
same total RNA samples fromwhich poly(A) RNA had been selected.
Similar results were obtained in all respects (data not shown).
Therefore, the reduction in IE2 proteins in cells treated with XMD7-
1 was associated with reduction in RNA transcription across the
entire HCMV genome and not with reduction of speciﬁc exon-exon
junctions required for production of IE2 mRNAs.
3.6. Examination of CDK inhibition by XMD7 compounds
Production of IE2 proteins, but not IE1, is compromised when
HCMV infected cells are treated with the broad-spectrum cyclin-
dependent kinase (CDK) inhibitor roscovitine (Sanchez and Spector,
2006), suggesting that CDK inhibition and cell cycle arrest are
related to inhibition of IE2 production. We found that XMD7
compounds inhibited CDK7 (Fig. 2AeC, indicated with crosses), but
not other CDK proteins (Tables S4eS6), and that treatment of un-
infected cells with XMD7 compounds had no effect of cell prolif-
eration as determined using MTT assays (data not shown).
Therefore, CDK inhibition upon treatment of infected cells with
XMD7 compounds was unlikely to be related to the anti-HCMV
activity of XMD7 compounds.
3.7. Investigation of HCMV protein production
We then investigated how suppression of HCMV transcription
and IE2 protein production in the presence of XMD7-1 affected
production of certain early (UL44), delayed early (UL84 and pp65)
and late (pp28) HCMV proteins. IE2-86 is required for initiation of
the viral transcriptional cascade and, therefore, is required for
expression of all viral proteins (Heider et al., 2002). Moreover, IE2-
86 and IE2-40 are required for the post-translational stabilization of
UL84 (Sanders et al., 2008; Sanders and Spector, 2010) and deletion
of IE2-60 and IE-40 results in suppression of pp65 production
(White et al., 2007). IE2-60 and IE2-40 are not required for efﬁcient
expression of either UL44 or pp28 (White et al., 2007). Using
western blotting we found less than 2-fold difference in accumu-
lation of UL84 (Fig. 3B), but a 2-fold decrease in both UL44 and pp65
expression and a 10-fold decrease in pp28 expression (Fig. 3D), in
HCMV infected cells treated with XMD7-1 compared to HCMV
infected cells treated with DMSO. We found similar phenotypes
when lysates of infected cells treated with either XMD7-2 or
XMD7-27 were assayed (data not shown). Therefore, treatment of
infected cells with XMD7 compounds had no obvious effect on IE1
or UL84 production, but resulted in suppression of all other HCMV
proteins assayed with the reduction in pp28 production being
greater than that of any other protein. Thus, treatment with XMD7
compounds inhibited transcription across the entire HCMV
genome, but did not compromise production of all HCMV proteins.
4. Discussion
Our screen identiﬁed a number of compounds that positively or
negatively inﬂuenced HCMV protein production and also identiﬁed
a number of compounds that are cytotoxic to HCMV infected cells.
As the compounds that were screened are largely uncharacterized,
further mining of our data will identify the relationship between
compound structures, compound targets, anti-HCMV activity and
cytotoxicity.
The XMD7 compounds are novel anti-HCMV compounds that
can efﬁciently inhibit HCMV replication. To our knowledge this is
the ﬁrst report identifying 5-aminopyrazine compounds with anti-
HCMV activity. No other compounds structurally related to XMD7
were assayed in our screen. Therefore, further 5-aminopyrazine
compounds must be assayed to discover the structure-activity
relationship that dictates the anti-HCMV activity of XMD7 com-
pounds. This will also allow design of compounds with improved
anti-HCMV activity and will aid identiﬁcation of kinase targets
required for anti-HCMV activity.
We found that the XMD7 compounds display poly-
pharmacology. Each of the kinase proteins potently inhibited by
XMD7 compounds will have to be assayed alone and in combina-
tion to discover the anti-HCMV target of the XMD7 compounds.
Many of these kinase proteins have not previously been reported to
be involved in HCMV replication. Therefore, assaying the require-
ment for many of these kinase proteins during HCMV replication
may identify cellular kinase proteins hitherto not recognized to be
involved in HCMV replication.
We propose that the mechanism of action of XMD7 com-
pounds involves inhibiting production of IE2 proteins, which
leads to a defect in transcription from the HCMV genome and a
defect in production of certain HCMV proteins (UL44, pp65 and
pp28, but not IE1 or UL84). This is somewhat consistent with an
essential role for IE2-86 in viral transcriptional transactivation
(Heider et al., 2002). However, it is unclear why production of all
HCMV proteins is not compromised. IE2-60 and IE2-40 have direct
roles in production of UL84 (Sanders et al., 2008; Sanders and
Spector, 2010). It is possible that there was sufﬁcient production
of IE2 proteins to maintain efﬁcient production of UL84 in the
presence of XMD7 compounds. However, it is unclear why levels
of IE1 were not affected. Also, a notable observation was that
suppression of pp28 production was greater than that observed
for UL44 and pp65. Deletion of HCMV protein UL26 from the
HCMV genome results in hypophosphorylation of pp28 during
HCMV replication, which results in instability of pp28 (Munger
et al., 2006). Thus, it is possible that treatment of HCMV infec-
ted cells with XMD7 compounds also leads to inhibition of UL26
function, or inhibition of the as yet unidentiﬁed kinase respon-
sible for pp28 phosphorylation, which results in suppression of
pp28 production.
6-aminoquinolone compounds (Loregian et al., 2010; Massari
et al., 2013; Mercorelli et al., 2014) and repurposed bioactive
small molecules (Mercorelli et al., 2016) that inhibit IE2 transcrip-
tional transactivation and have anti-HCMV activity have been re-
ported. These compounds are structurally dissimilar to XMD7
compounds and, in contrast to XMD7 compounds, do not inhibit
IE2 production in HCMV infected cells (Loregian et al., 2010;
Mercorelli et al., 2016). Therefore, these compounds have a
different mechanism of action compared to XMD7 compounds.
These previously identiﬁed compounds and our present work un-
derscore that targeting IE2 production or function is a valid route to
inhibiting HCMV replication. Further development of these com-
poundswill illuminate themolecular basis of their action, including
the direct or indirect effects these compounds have on viral repli-
cation and cell function.
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